{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:51:51Z","timestamp":1790077911100,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"REIPI","award":["Spanish Network for Research in Infectious Diseases"],"award-info":[{"award-number":["Spanish Network for Research in Infectious Diseases"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11046-019-00331-0","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T08:02:57Z","timestamp":1553241777000},"page":"239-250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aerosolized Lipid Amphotericin B for Complementary Therapy and\/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience"],"prefix":"10.1007","volume":"184","author":[{"given":"E.","family":"Venanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00edn-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Maiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. G\u00f3mez-Garc\u00eda","family":"de la Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Filigheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6959-5263","authenticated-orcid":false,"given":"J.","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"10020","key":"331_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE). Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"331_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"331_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"331_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.healun.2008.11.004","volume":"28","author":"V Monforte","year":"2009","unstructured":"Monforte V, Ussetti P, L\u00f3pez R, Gavalda J, Bravo C, de Pablo A, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transpl. 2009;28(2):170\u20135.","journal-title":"J Heart Lung Transpl"},{"issue":"3","key":"331_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/08982104.2017.1327543","volume":"27","author":"JP Adler-Moore","year":"2017","unstructured":"Adler-Moore JP, Proffitt RT, Olson JA, Jensen GM. Tissue pharmacokinetic and pharmacodynamics of Ambisome (L-AmBis) in uninfected and infected animals and their effects on dosing regimens. J Liposome Res. 2017;27(3):195\u2013209.","journal-title":"J Liposome Res"},{"key":"331_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.healun.2009.11.603","volume":"29","author":"V Monforte","year":"2010","unstructured":"Monforte V, Ussetti P, GavaldA J, Bravo C, Laporta R, Len O, et al. Feasibility, tolerability and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transpl. 2010;29:523\u201330.","journal-title":"J Heart Lung Transpl"},{"key":"331_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","volume":"9","author":"CM Lowry","year":"2007","unstructured":"Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis. 2007;9:121\u20135.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"331_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/tri.12679","volume":"29","author":"M Peghin","year":"2016","unstructured":"Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, et al. 10\u00a0years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation. Transpl Int. 2016;29(1):51\u201362.","journal-title":"Transpl Int"},{"issue":"2","key":"331_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","volume":"77","author":"RH Drew","year":"2004","unstructured":"Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung transplant recipients. Transplantation. 2004;77(2):232\u20137.","journal-title":"Transplantation"},{"issue":"11","key":"331_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/TP.0b013e3181f995ea","volume":"90","author":"S Husain","year":"2010","unstructured":"Husain S, Capitano B, Corcoran T, Studer SM, Crespo M, Johnson B, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation. 2010;90(11):1215\u20139.","journal-title":"Transplantation"},{"issue":"Suppl 4","key":"331_CR11","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1086\/421958","volume":"39","author":"JR Perfect","year":"2004","unstructured":"Perfect JR, Dodds Ashley E, Drew R. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. Clin Infect Dis. 2004;39(Suppl 4):S207\u201310.","journal-title":"Clin Infect Dis"},{"key":"331_CR12","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1086\/586739","volume":"46","author":"BJ Rijnders","year":"2008","unstructured":"Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary Aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46:1401\u20138.","journal-title":"Clin Infect Dis"},{"key":"331_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.pupt.2008.09.001","volume":"21","author":"L Slobbe","year":"2008","unstructured":"Slobbe L, Boersma E, Rijnders BJ. Tolerability of prophylactic aerosolized liposomal amphotericin-B and impact on pulmonary function: data from a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21:855\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"331_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2015.02.023","volume":"46","author":"GL Chong","year":"2015","unstructured":"Chong GL, Broekman F, Polinder S, Doorduijn JK, Lugtenburg PJ, Verbon A, et al. Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: efficacy and cost effectiveness in real-life. Int J Antimicrob Agents. 2015;46(1):82.","journal-title":"Int J Antimicrob Agents"},{"key":"331_CR15","unstructured":"Ruiz I, Rovira M, V\u00e1zquez L, de la C\u00e1mara R, Diaz-Mediavilla J, et al. Nebulized liposomal amphotericin B (L-AmB) as antifungal prophylaxis for high risk haematological Patients. 49th ICAAC Abstracts, Session, Sept 2009. San Francisco, USA."},{"issue":"5","key":"331_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3109\/02770903.2015.1127935","volume":"53","author":"B Ram","year":"2016","unstructured":"Ram B, Aggarwal AN, Dhooria S, Sehgal IS, Garg M, Behera D, Chakrabarti A, Agarwal R. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis. J Asthma. 2016;53(5):517\u201324.","journal-title":"J Asthma"},{"issue":"3","key":"331_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1399-3062.2007.00290.x","volume":"10","author":"KM Ho","year":"2008","unstructured":"Ho KM, Duff O, Chambers D, Murray R. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals. Transpl Infect Dis. 2008;10(3):168\u201376.","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"331_CR18","first-page":"44","volume":"23","author":"D Canetti","year":"2015","unstructured":"Canetti D, Cazzadori A, Adami I, Lifrieri F, Cristino S, Concia E. Aerosolized amphotericin B lipid complex and invasive pulmonary aspergillosis: a case report. Infez Med. 2015;23(1):44\u20137.","journal-title":"Infez Med"},{"issue":"10","key":"331_CR19","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/phar.1309","volume":"33","author":"A Safdar","year":"2013","unstructured":"Safdar A, Rodriguez GH. Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation. Pharmacotherapy. 2013;33(10):1035\u201343.","journal-title":"Pharmacotherapy"},{"key":"331_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-017-0117-9","author":"C Godet","year":"2017","unstructured":"Godet C, Cateau E, Rammaert B, Grosset M, Le Moal G, B\u00e9raud G, et al. Nebulized liposomal amphotericin B for treatment of pulmonary infection caused by hormographiella aspergillata: case report and literature review. Mycopathologia. 2017. \n                    https:\/\/doi.org\/10.1007\/s11046-017-0117-9\n                    \n                  .","journal-title":"Mycopathologia"},{"issue":"5","key":"331_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1164\/rccm.201311-2086LE","volume":"189","author":"S Hanada","year":"2014","unstructured":"Hanada S, Uruga H, Takaya H, Miyamoto A, Morokawa N, Kurosaki A, et al. Nebulized liposomal amphotericin B for treating Aspergillus empyema with bronchopleural fistula. Am J Respir Crit Care Med. 2014;189(5):607\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"331_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1179\/1973947814Y.0000000194","volume":"27","author":"R Casciaro","year":"2015","unstructured":"Casciaro R, Naselli A, Cresta F, Ros M, Castagnola E, Minicucci L. Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: case report and review of literature. J Chemother. 2015;27(5):307\u201311.","journal-title":"J Chemother"},{"issue":"12","key":"331_CR23","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw De","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"331_CR24","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.healun.2014.05.003","volume":"33","author":"P Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz P, Vena A, Cer\u00f3n I, Valerio M, Palomo J, Guinea J, et al. Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. J Heart Lung Transpl. 2014;33(10):1034\u201340.","journal-title":"J Heart Lung Transpl"},{"issue":"1","key":"331_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","volume":"186","author":"SI Blot","year":"2012","unstructured":"Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically Ill patients. Am J Respir Crit Care Med. 2012;186(1):56\u201364.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"331_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/cc10138","volume":"15","author":"P Bulpa","year":"2011","unstructured":"Bulpa P, Dive A. Diagnosis of invasive bronchial-pulmonary aspergillosis in patients with chronic obstructive respiratory diseases. Crit Care. 2011;15(2):420\u20132.","journal-title":"Crit Care"},{"issue":"6","key":"331_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/17425247.2015.995087","volume":"12","author":"AR Martin","year":"2015","unstructured":"Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12(6):889\u2013900.","journal-title":"Expert Opin Drug Deliv"},{"key":"331_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1517\/14740330903036083","volume":"8","author":"A Safdar","year":"2009","unstructured":"Safdar A, Shelburne S, Evans S, Dickey B. Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf. 2009;8:435\u201349.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"331_CR29","first-page":"3654","volume":"93","author":"S Schwartz","year":"1999","unstructured":"Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood. 1999;93(11):3654\u201361.","journal-title":"Blood"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-019-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-019-00331-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-019-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T01:37:51Z","timestamp":1567474671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-019-00331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1007\/s11046-019-00331-0","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]},"assertion":[{"value":"19 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}